BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Veritas Medicine Release: OvaRex MAb For Patients With Advanced Ovarian Cancer May Extend Remission Following Favorable Surgery And Chemotherapy


10/19/2005 5:13:05 PM

TOLEDO, Ohio--(BUSINESS WIRE)--March 21, 2005-- Toledo, Ohio Researchers Seeking New Standard of Care for Advanced Ovarian Cancer For the majority of patients with advanced ovarian cancer, the current standard of care and front-line treatments - surgery and chemotherapy - are not enough to control the high recurrence rate. Researchers at the Medical College of Ohio Hospital are further evaluating OvaRex(R) MAb (oregovomab), an investigational therapy, to determine the extent of remission in patients who have a favorable response to surgery and chemotherapy. They are also assessing survival, quality of life, immune response, and safety. Women with stage III or IV ovarian cancer, who qualify to participate in the ongoing clinical research, must begin taking the study medication within four to 12-weeks of completing their last dose of initial chemotherapy. For more information and pre-screening, visit www.OvarianCancerStudy.com.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES